Medigen Biotechnology (ROCO:3176) Total Stockholders Equity : NT$1,556 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Total Stockholders Equity?

Medigen Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$1,556 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Medigen Biotechnology's Book Value per Share for the quarter that ended in Mar. 2024 was NT$11.17. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Medigen Biotechnology's Debt-to-Equity for the quarter that ended in Mar. 2024 was 1.87.

Medigen Biotechnology Total Stockholders Equity Historical Data

The historical data trend for Medigen Biotechnology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Total Stockholders Equity Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,361.11

1,815.42

2,394.39

2,194.03

1,591.64

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															1,970.83	1,901.24	1,864.01	1,591.64	1,555.81

Medigen Biotechnology (ROCO:3176) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Medigen Biotechnology's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1555.805	-	0)	/	139.229
	=	11.17

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Medigen Biotechnology's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2196.464	+	709.739)	/	1555.805
	=	1.87

Medigen Biotechnology Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines